Benralizumab: Phase III data

Top-line data from the double-blind, international Phase III CALIMA trial in 1,306 patients ages >=12 with severe uncontrolled asthma showed that subcutaneous benralizumab for 52 weeks

Read the full 265 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE